|
Objective: To investigate the lipid-lowering particulate clinical efficacy and safety of treatment of hyperlipidemia ( spleen wet Sheng , phlegm and blood stasis syndrome) . Methods : 96 patients with hyperlipidemia ( Spleen wet Sheng , phlegm retention syndrome ) patients were randomly divided into experimental group ( lipid-lowering particle group, 48 cases ) and control group ( the slice group Zhibituo 48 cases) , for six weeks a course of treatment. The clinical efficacy observed before and after treatment , blood lipids , syndrome improve the situation. Results : lipid-lowering particle lipid total effective rate of 79.2% , the control group, the total effective rate of 77.1% . Lipid-lowering particles can significantly reduce serum TC , LDL- C and TG levels , but also reduce atherosclerosis index (AI), increased HDL -C . Its lipid-lowering effect with Erbitux control drug to lipid quite the difference was not statistically significant ( P > 0.05 ) . Lipid-lowering particles can significantly improve the TCM syndrome condition , can be effective in improving the symptoms of dizziness , heavy head , chest tightness , Oue hold the spit , pale mouth , eat less , significantly higher than the efficacy Zhibituo , the difference was statistically significant (P <0.01 or P <0.05). Conclusion : the lipid-lowering particles can effectively improve blood lipid circumstances applicable to the treatment of hyperlipidemia ( spleen wet Sheng , phlegm and blood stasis syndrome) .
|